Roche is set to pay out $750 million upfront to acquire digital pathology specialist Path AI in a move by the pharma giant to accelerate the use of artificial intelligence in diagnostic algorithms.
Entrada identified lower-than-expected plasma exposure in juvenile DMD patients as the cause of the lackluster data. Exposure ...
For people living with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF), the only treatment option is a regimen that can include up to 40 pills a day. With a $250 million investment ...
BeOne Medicines has shaken up its early pipeline, dropping five phase 1 cancer programs and stopping a phase 2 arthritis ...
Ascendis Pharma has ended internal development of its IL-2 candidate, pivoting away from oncology and calling time on an ...
The buyout, which includes up to $2.15 billion in milestones, will give Bayer control of an eye disease implant that Perfuse ...
A phase 2 trial of Avalo Therapeutics’ hidradenitis suppurativa (HS) candidate hit its primary endpoint, emboldening the ...
A new bipartisan bill could end the import of primates for U.S. research, targeting the roughly 20,000 monkeys brought into the country each year for laboratories or their suppliers. | A new ...
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s heart—oligonucleotides. The British drugmaker is paying $55 million upfront to China’s ...
In the last three years, CellCentric CEO Will West has been on a journey that has transformed how he thinks about the future ...
Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
Madrigal Pharmaceuticals' hunger for fresh metabolic dysfunction-associated steatohepatitis (MASH) drugs shows no sign of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results